Authors:
Berruti, A
Dogliotti, L
Mosca, A
Gorzegno, G
Bollito, E
Mari, M
Tarabuzzi, R
Poggio, M
Torta, M
Fontana, D
Angeli, A
Citation: A. Berruti et al., Potential clinical value of circulating chromogranin A in patients with prostate carcinoma, ANN ONCOL, 12, 2001, pp. S153-S157
Authors:
Bollito, E
Berruti, A
Bellina, A
Mosca, A
Leonardo, E
Tarabuzzi, R
Cappia, S
Mari, M
Tampellini, M
Fontana, D
Gubetta, L
Angeli, A
Dogliotti, L
Citation: E. Bollito et al., Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma, ANN ONCOL, 12, 2001, pp. S159-S164
Authors:
Berruti, A
Dogliotti, L
Mosca, A
Tarabuzzi, R
Torta, M
Mari, M
Gorzegno, G
Fontana, D
Angeli, A
Citation: A. Berruti et al., Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients, PROSTATE, 47(3), 2001, pp. 205-211
Authors:
Berruti, A
Dogliotti, L
Tucci, M
Tarabuzzi, R
Fontana, D
Angeli, A
Citation: A. Berruti et al., Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates, J UROL, 166(6), 2001, pp. 2023-2031
Authors:
Berruti, A
Dogliotti, L
Fasolis, G
Mosca, A
Tarabuzzi, R
Torta, M
Mari, M
Fontana, D
Angeli, A
Citation: A. Berruti et al., Changes in free and free-to-total prostate specific antigen after androgendeprivation or chemotherapy in patients with advanced prostate cancer, J UROL, 161(1), 1999, pp. 176-181